cat no | io1035, io1036
ioMicroglia TREM2 R47H/R47H are opti-ox deterministically programmed microglia carrying a genetically engineered homozygous R47H mutation in the TREM2 gene encoding the triggering receptor expressed on myeloid cells 2 protein. The TREM2 R47H mutation has been linked with increased risk of late-onset Alzheimer's disease (AD).
These cells offer a functional, rapidly maturing, and disease relevant system to study the role of the TREM2 R47H mutation in late-onset AD, alongside a genetically matched wild-type control.
Two clones are available, all genetically matched to the wild type control, ioMicroglia. The disease model cells and the wild-type control offer a physiologically relevant model to investigate the impact of the TREM2 R47H mutation on cellular and molecular mechanisms and function in late-onset AD.
Confidently investigate your phenotype of interest across multiple clones with our disease model clone panel. Detailed characterisation data (below) and bulk RNA sequencing data (upon request) help you select specific clones if required.
per vial
A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at orders@ÎÞÓǶÌÊÓƵ.
Making True Comparisons
Pair the ioDisease Model Cells with the genetically matched wild-type ioMicroglia to directly investigate the effect of the mutant TREM2 protein on late-onset AD.
Quick
Rapidly maturing cells that are ready to use within 10 days post-revival, in mono- and co-cultures.
Functional
Disease model cells display key phagocytic and cytokine secretion functions.
ioMicroglia TREM2 R47H/R47H are delivered in a cryopreserved format and are programmed to rapidly mature upon revival in the recommended media. The protocol for the generation of these cells is a three-phase process: an Induction phase that is carried out at ÎÞÓǶÌÊÓƵ, Phase 1: Stabilisation for 24 hours, Phase 2: Maturation for a further 9 days, Phase 3: the Maintenance phase. Cells are ready to use from day 10.
Disease model cells express key microglia markers comparably to the genetically matched wild-type control
Immunofluorescent staining on day 10 post-revival demonstrates similar homogenous expression of microglia markers P2RY12 and IBA1 and ramified morphology in both disease model clones compared to the genetically matched wild-type (WT) control. 100X magnification.
Disease model cells show expected ramified morphology by day 10
Both disease model clones mature rapidly and key ramified morphology can be identified by day 4 and continues through to day 10, similarly to the WT control. Day 1 to 10 post-thawing; 100x magnification.
Disease model cells show a similar proportion of phagocytosis to the genetically matched wild-type control
Phagocytosis was analysed at day 10 post-revival after incubation with 1 µg/0.33 cm2 pHrodo RED labelled E. coli particles for 24 hours +/- cytochalasin D control. The graph displays the proportion of cells phagocytosing E. coli particles over 24 hours and shows that both disease model clones display a similar proportion of phagocytosis to the WT control. Images were acquired every 30 mins on the Incucyte® looking at red fluorescence and phase contrast. Three technical replicates were performed per experiment.
Disease model cells show a similar degree of phagocytosis of E. coli particles to the genetically matched wild-type control
Phagocytosis was analysed at day 10 post-revival after incubation with 1 µg/0.33 cm2 pHrodo RED labelled E. coli particles for 24 hours +/- cytochalasin D control. The graph displays the fluorescence intensity per cell displaying degree of phagocytosis per cell and shows that both disease model clones display a similar degree of phagocytosis per cell to the WT control. Images were acquired every 30 mins on the Incucyte® looking at red fluorescence and phase contrast. Three technical replicates were performed experiment.
Cytokine secretion was analysed at day 10 post-revival after stimulation with LPS 100 ng/ml and IFNɣ 20 ng/ml for 24 hours. This revealed that both disease model clones secrete the predominantly pro-inflammatory cytokines, IL-6, IL-8, IL-1β, and TNF⺠at a similar level to the WT control whereas IL-12p70 appears to be secreted at a lower level than the WT control. The anti-inflammatory IL-10 is secreted at a lower level by clone CL45 but at a higher level by clone CL17 than the WT control. Supernatants were harvested and analysed using MSD V-plex Proinflammatory Kit. Three technical replicates were performed experiment.
Starting material
Human iPSC line
Seeding compatibility
6, 12, 24, 96 & 384 well plates
Shipping info
Dry ice
Donor
Caucasian adult male (skin fibroblast)
Vial size
Small: >1.5 x 10ⶠviable cells
Quality control
Sterility, protein expression (ICC), functional phagocytosis and cytokine secretion assays
Differentiation method
opti-ox deterministic cell programming
Recommended seeding density
37,000 to 39,500 cells/cm²
User storage
LN2 or -150°C
Format
Cryopreserved cells
Product use
ioCells are for research use only
Genetic modification
Homozygous R47H mutation in the TREM2 gene
Applications
Alzheimer's disease modelling
Drug discovery and development
Neuroinflammation modelling
Phagocytosis assays
Cytokine response assays
Co-culture studies
Available clones
io1035S: ioMicroglia TREM2 R47H/R47H (CL17)
io1036S: ioMicroglia TREM2 R47H/R47H (CL45)
Elise Malavasi, PhD
Principal Scientist
Concept Life Sciences
ÎÞÓǶÌÊÓƵ | Medicines Discovery Catapult
2024
In this GEN webinar, hear from our distinguished expert, Dr Matthias Pawlowski, and learn about the emerging role of microglia in the pathogenesis of Alzheimer’s disease and their potential as a therapeutic target to treat this disease effectively.
Consistent. Defined. Scalable.